Anadys Pharmaceuticals/Roche
On October 17, 2011, Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) entered into a definitive merger agreement to be acquired by Roche (OTCBB: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at $3.70 per share.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
The $3.70 per share cash offer price represents a 256% premium over the closing price of $1.04 on October 14, 2011.
Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
Closing is expected in Q411.
Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors
